Allspring Global Investments Holdings, LLC Arbutus Biopharma Corp Transaction History

Allspring Global Investments Holdings, LLC

$62.1 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 18, 2023	BUY	$2.24 - $3.06 $212 - $290	95 New	95 $0
Q4 2022 Jan 23, 2023	SELL	$1.91 - $2.85 $42 - $62	-22 Reduced 2.15%	1,000 $0
Q2 2022 Jul 25, 2022	SELL	$1.98 - $3.17 $168,450 - $269,690	-85,076 Reduced 98.81%	1,022 $2,000
Q1 2022 May 02, 2022	SELL	$2.42 - $3.98 $20,843 - $34,279	-8,613 Reduced 9.09%	86,098 $256,000
Q4 2021 Jan 28, 2022	BUY	$3.11 - $4.61 $294,551 - $436,617	94,711 New	94,711 $368,000

Others Institutions Holding ABUS

# of Institutions

155

Shares Held

99.5M

Call Options Held

2.31M

Put Options Held

525K

Morgan Stanley New York, NY

21.7M
Shares

$69.2 Million
0.01% of portfolio
Whitefort Capital Management, LP New York, NY

12.9M
Shares

$41 Million
26.34% of portfolio
Black Rock Inc. New York, NY

11.6M
Shares

$36.9 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

8.92M
Shares

$28.5 Million
0.0% of portfolio
Two Seas Capital LP Rye, NY

8.39M
Shares

$26.8 Million
10.86% of portfolio

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $478M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.

Account